{"id":"cytisinicline-and-exercise","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL497939","moleculeType":"Small molecule","molecularWeight":"190.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytisinicline binds to nicotinic acetylcholine receptors with lower affinity than nicotine, reducing the rewarding effects of smoking and alleviating withdrawal symptoms. When combined with structured exercise, the intervention leverages both pharmacological and behavioral mechanisms to improve quit rates and long-term abstinence in smokers.","oneSentence":"Cytisinicline is a partial agonist of nicotinic acetylcholine receptors that reduces nicotine craving and withdrawal symptoms, combined with exercise to enhance smoking cessation outcomes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:37.522Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smoking cessation in combination with exercise intervention"}]},"trialDetails":[{"nctId":"NCT03654105","phase":"PHASE2","title":"Screening and Multiple Intervention on Lung Epidemics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2019-07-23","conditions":"Inflammation, Smoking Cessation, Diet Modification","enrollment":2000},{"nctId":"NCT06579846","phase":"PHASE4","title":"12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-01-01","conditions":"Smoking Cessation","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cytisinicline","Exercise"],"phase":"marketed","status":"active","brandName":"Cytisinicline and exercise","genericName":"Cytisinicline and exercise","companyName":"Maimónides Biomedical Research Institute of Córdoba","companyId":"maim-nides-biomedical-research-institute-of-c-rdoba","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cytisinicline is a small molecule that acts as a partial agonist of the neuronal acetylcholine receptor, specifically the alpha4/beta2 subtype. It has been studied in clinical trials for various conditions, including smoking cessation, inflammation, and lung cancer, often in combination with other interventions such as diet modification and physical activity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":232,"withResults":8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}